Stock report · Delisted · Nasdaq
Y mAbs Therapeutics (YMAB)
8.61USD Delisted Final close · Sep 15, 2025
YMAB no longer trades. Y mAbs Therapeutics was delisted from the Nasdaq in September 2025.
All prices on this page are historical. The last trade was on September 15, 2025, at $8.61.
YMAB stock price history
Final trading statistics
- Final close
- $8.61
- Final trading day
- Sep 15, 2025
- Market cap at delisting
- $391.22M
- Shares outstanding
- 45.44M
- Final 52-week range
- $3.55 – $16.11
- Avg. volume (final 3 mo.)
- 905,069
- All-time high
- $54.26 · Dec 2020
- All-time low
- $2.83 · Mar 2023
- Return since IPO
- -64.1%
- Beta
- 0.53
- Book value / share
- $1.93
- Price / book
- 4.47
About Y mAbs Therapeutics
Y-mAbs Therapeutics, Inc. was a commercial-stage biopharmaceutical company focused on radioimmunotherapy and antibody-based cancer treatments. Its marketed drug DANYELZA, given with granulocyte-macrophage colony-stimulating factor, treated children with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
DANYELZA was also in Phase II for second-line relapsed osteosarcoma. Other programs included GD2-SADA in Phase I for GD2 positive solid tumors, Omburtamab for central nervous system and leptomeningeal spread of neuroblastoma, CD38-SADA, a GD2-GD3 vaccine, and the SADA PRIT platform for delivering radiation to tumors.
It held licenses from Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology and operated in the U.S., Western Europe, Eastern Asia, Latin America, Western Asia and beyond. Incorporated in 2015 and based in Princeton, New Jersey, it became a subsidiary of SERB S.A.S. as of September 15, 2025. Its stock was delisted from the Nasdaq that month, with a final trade on September 15, 2025 at $8.61.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Princeton, NJ
- Employees
- 104
- IPO date
- September 21, 2018
- Delisted
- September 15, 2025
- SEC CIK
- 1722964
Y mAbs Therapeutics financials before the delisting
The last 5 fiscal years Y mAbs Therapeutics reported as a public company, fiscal year ending December.
YMAB revenue and net income
YMAB earnings per share
YMAB annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $87.69M | −$29.7M | −$0.67 |
| FY2023 | $84.82M | −$21.4M | −$0.49 |
| FY2022 | $65.27M | −$96.3M | −$2.18 |
| FY2021 | $34.90M | −$56.3M | −$2.72 |
| FY2020 | $20.75M | −$119.3M | −$2.97 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Y mAbs Therapeutics stock FAQ
What happened to Y mAbs Therapeutics stock?
Y mAbs Therapeutics was delisted from the Nasdaq in September 2025. The final close was $8.61 on September 15, 2025.
Can I still buy YMAB stock?
No. YMAB is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on September 15, 2025.
What was the last price of YMAB?
YMAB last closed at $8.61 on September 15, 2025, which valued the company at about $391.22M.
How did Y mAbs Therapeutics do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, Y mAbs Therapeutics reported revenue of $87.69M and net income of −$29.7M.
When did Y mAbs Therapeutics go public?
Y mAbs Therapeutics shares started trading on September 21, 2018.
YMAB no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.